bi 831266
Small moleculeexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00756223)
Timeline
Indications
Mechanism of action
AURKA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 831266
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02358720 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2014 | University of Heidelberg |
| NCT02079220 | Phase 2 | Mar 1, 2014 | Sanofi, University of Pittsburgh |
| NCT01176799 | Phase 2 | Aug 1, 2010 | National University of Singapore |
| NCT01069081 | Phase 2 | Aug 1, 2009 | Fudan University, Istituto Superiore di Sanità |
| NCT00756223 | Phase 1 | Nov 1, 2008 | Boehringer Ingelheim |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 2008 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Istituto Superiore di Sanità | Academic/Hospital | 1 | 0 | 1 | 2009 |
| National University of Singapore | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Sanofi | For profit | 1 | 0 | 1 | 2014 |
| University of Heidelberg | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2014 |
7 organizations
Page 1 / 1